J. Li, R. Nation, J. Turnidge, R. Milne, K. Coulthard et al., Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections, The Lancet Infectious Diseases, vol.6, issue.9, pp.589-601, 2006.
DOI : 10.1016/S1473-3099(06)70580-1

R. Nation, J. Li, O. Cars, W. Couet, M. Dudley et al., Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus, The Lancet Infectious Diseases, vol.15, issue.2, pp.225-259, 2015.
DOI : 10.1016/S1473-3099(14)70850-3

H. He, J. Li, R. Nation, J. Jacob, G. Chen et al., Pharmacokinetics of four different brands of colistimethate and formed colistin in rats, Journal of Antimicrobial Chemotherapy, vol.68, issue.10, pp.2311-2318, 2013.
DOI : 10.1093/jac/dkt207

M. Rhouma, F. Beaudry, W. Theriault, N. Bergeron, S. Laurent-lewandowski et al., Gastric stability and oral bioavailability of colistin sulfate in pigs challenged or not with Escherichia coli O149: F4 (K88), Research in Veterinary Science, vol.102, pp.173-81, 2015.
DOI : 10.1016/j.rvsc.2015.08.005

S. Shah, A. Henslee, P. Spicer, S. Yokota, S. Petrichenko et al., Effects of Antibiotic Physicochemical Properties on Their Release Kinetics from Biodegradable Polymer Microparticles, Pharmaceutical Research, vol.145, issue.Suppl 2, pp.3379-89, 2014.
DOI : 10.1007/s11095-014-1427-y

T. Velkov, K. Roberts, R. Nation, P. Thompson, and J. Li, Pharmacology of polymyxins: new insights into an ???old??? class of antibiotics, Future Microbiology, vol.8, issue.6, pp.711-735, 2013.
DOI : 10.2217/fmb.13.39

J. Li, R. Nation, R. Milne, J. Turnidge, and K. Coulthard, Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria, International Journal of Antimicrobial Agents, vol.25, issue.1, pp.11-25, 2005.
DOI : 10.1016/j.ijantimicag.2004.10.001

P. Bergen, C. Landersdorfer, J. Zhang, M. Zhao, H. Lee et al., Pharmacokinetics and pharmacodynamics of ???old??? polymyxins: what is new?, Diagnostic Microbiology and Infectious Disease, vol.74, issue.3, pp.213-236, 2012.
DOI : 10.1016/j.diagmicrobio.2012.07.010

P. Bergen, C. Landersdorfer, H. Lee, J. Li, and R. Nation, ???Old??? antibiotics for emerging multidrug-resistant bacteria, Current Opinion in Infectious Diseases, vol.25, issue.6, pp.626-659, 2012.
DOI : 10.1097/QCO.0b013e328358afe5
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4242550

S. Yapa, J. Li, C. Porter, R. Nation, K. Patel et al., Population Pharmacokinetics of Colistin Methanesulfonate in Rats: Achieving Sustained Lung Concentrations of Colistin for Targeting Respiratory Infections, Antimicrobial Agents and Chemotherapy, vol.57, issue.10, pp.5087-95, 2013.
DOI : 10.1128/AAC.01127-13

. Drugbank and . Colistimethate, https://www.drugbank.ca/drugs/ DB01111, 2016.

. Drugbank and . Colistin, https://www.drugbank.ca/drugs/DB00803, 2016.

S. Wallace, J. Li, R. Nation, R. Prankerd, T. Velkov et al., Self-Assembly Behavior of Colistin and Its Prodrug Colistin Methanesulfonate: Implications for Solution Stability and Solubilization, The Journal of Physical Chemistry B, vol.114, issue.14, pp.4836-4876, 2010.
DOI : 10.1021/jp100458x

S. Wallace, J. Li, C. Rayner, K. Coulthard, and R. Nation, Stability of Colistin Methanesulfonate in Pharmaceutical Products and Solutions for Administration to Patients, Antimicrobial Agents and Chemotherapy, vol.52, issue.9, pp.3047-51, 2008.
DOI : 10.1128/AAC.00103-08

P. Gobin, F. Lemaitre, S. Marchand, W. Couet, and J. Olivier, Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography tandem mass spectrometry (LC?MS/ MS), Antimicrob Agents Chemother, vol.22, issue.54, pp.1941-1949, 2010.

J. Li, R. Milne, R. Nation, J. Turnidge, K. Coulthard et al., Simple Method for Assaying Colistin Methanesulfonate in Plasma and Urine Using High-Performance Liquid Chromatography, Antimicrobial Agents and Chemotherapy, vol.46, issue.10, pp.3304-3311, 2002.
DOI : 10.1128/AAC.46.10.3304-3307.2002
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC128774

J. Li, R. Milne, R. Nation, J. Turnidge, T. Smeaton et al., Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate, Journal of Antimicrobial Chemotherapy, vol.53, issue.5, pp.837-877, 2004.
DOI : 10.1093/jac/dkh167

D. Chepyala, I. Tsai, H. Sun, S. Lin, and C. Kuo, Development and validation of a high-performance liquid chromatographyfluorescence detection method for the accurate quantification of colistin in human plasma, J Chromatogr B Anal Technol Biomed Life Sci, vol.1, issue.980, pp.48-54, 2015.

J. Li, R. Milne, R. Nation, J. Turnidge, K. Coulthard et al., A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography, Journal of Chromatography B: Biomedical Sciences and Applications, vol.761, issue.2, pp.167-75, 2001.
DOI : 10.1016/S0378-4347(01)00326-7

T. Van-den-meersche, E. Pamel, C. Poucke, L. Herman, M. Heyndrickx et al., Development, validation and application of an ultra high performance liquid chromatographic-tandem mass spectrometric method for the simultaneous detection and quantification of five different classes of veterinary antibiotics in swine manure, Journal of Chromatography A, vol.1429, pp.248-57, 1429.
DOI : 10.1016/j.chroma.2015.12.046

B. Jansson, M. Karvanen, O. Cars, D. Plachouras, and L. Friberg, Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC/MS/MS, Journal of Pharmaceutical and Biomedical Analysis, vol.49, issue.3, pp.760-767, 2009.
DOI : 10.1016/j.jpba.2008.12.016

S. Marchand, P. Gobin, J. Brillault, S. Baptista, C. Adier et al., Aerosol Therapy with Colistin Methanesulfonate: a Biopharmaceutical Issue Illustrated in Rats, Antimicrobial Agents and Chemotherapy, vol.54, issue.9, pp.3702-3709, 2010.
DOI : 10.1128/AAC.00411-10

R. Nation, T. Velkov, and J. Li, Colistin and Polymyxin B: Peas in a Pod, or Chalk and Cheese?, Clinical Infectious Diseases, vol.59, issue.1, pp.88-94, 2014.
DOI : 10.1093/cid/ciu213
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4305129

A. Bialvaei, S. Kafil, and H. , Colistin, mechanisms and prevalence of resistance, Current Medical Research and Opinion, vol.31, issue.4, pp.707-728, 2015.
DOI : 10.1185/03007995.2015.1018989

R. Dixon and I. Chopra, Leakage of periplasmic proteins from Escherichia coli mediated by polymyxin B nonapeptide., Antimicrobial Agents and Chemotherapy, vol.29, issue.5, pp.781-789, 1986.
DOI : 10.1128/AAC.29.5.781

C. Chen and D. Feingold, Locus of Divalent Cation Inhibition of the Bactericidal Action of Polymyxin B, Antimicrobial Agents and Chemotherapy, vol.2, issue.5, pp.331-336, 1972.
DOI : 10.1128/AAC.2.5.331

M. Schindler and M. Osborn, Interaction of divalent cations and polymyxin B with lipopolysaccharide, Biochemistry, vol.18, issue.20, pp.4425-4455, 1979.
DOI : 10.1021/bi00587a024

S. Davis, A. Iannetta, and R. Wedgwood, Activity of Colistin against Pseudomonas aeruginosa: Inhibition by Calcium, Journal of Infectious Diseases, vol.124, issue.6, pp.610-612, 1971.
DOI : 10.1093/infdis/124.6.610

A. Clausell, M. Garcia-subirats, M. Pujol, M. Busquets, F. Rabanal et al., Gram-Negative Outer and Inner Membrane Models:?? Insertion of Cyclic Cationic Lipopeptides, The Journal of Physical Chemistry B, vol.111, issue.3, pp.551-63, 2007.
DOI : 10.1021/jp064757+

A. Peterson, R. Hancock, and E. Mcgroarty, Binding of polycationic antibiotics and polyamines to lipopolysaccharides of Pseudomonas aeruginosa, J Bacteriol, vol.164, issue.3, pp.1256-61, 1985.

M. Gough, R. Hancock, and N. Kelly, Antiendotoxin activity of cationic peptide antimicrobial agents, Infect Immun, vol.64, issue.12, pp.4922-4929, 1996.

N. Martis, S. Leroy, and V. Blanc, Colistin in multi-drug resistant Pseudomonas aeruginosa blood-stream infections, Journal of Infection, vol.69, issue.1, pp.1-12, 2014.
DOI : 10.1016/j.jinf.2014.03.001

K. Gardiner, P. Erwin, N. Anderson, M. Mccaigue, M. Halliday et al., Lactulose as an antiendotoxin in experimental colitis, British Journal of Surgery, vol.90, issue.4, pp.469-72, 1995.
DOI : 10.1002/bjs.1800820413

P. Escartin, J. Rodriguez-montes, V. Cuervas-mons, I. Rossi, J. Alvarez-cienfuegos et al., Effect of colistin on reduction of biliary flow induced by endotoxin ofE. coli, Digestive Diseases and Sciences, vol.69, issue.10, pp.875-884, 1982.
DOI : 10.1007/BF01316569

J. Lopes and W. Inniss, Electron microscopy of effect of polymyxin on Escherichia coli lipopolysaccharide, J Bacteriol, vol.100, issue.2, pp.1128-1137, 1969.

D. Storm, K. Rosenthal, and P. Swanson, Polymyxin and Related Peptide Antibiotics, Annual Review of Biochemistry, vol.46, issue.1, pp.723-63, 1977.
DOI : 10.1146/annurev.bi.46.070177.003451

Z. Deris, J. Akter, S. Sivanesan, K. Roberts, P. Thompson et al., A secondary mode of action of polymyxins against Gram-negative bacteria involves the inhibition of NADH-quinone oxidoreductase activity, The Journal of Antibiotics, vol.251, issue.2, pp.147-51, 2014.
DOI : 10.1074/jbc.M411217200

Y. Cai, W. Lee, and A. Kwa, Polymyxin B versus colistin: an update, Expert Review of Anti-infective Therapy, vol.13, issue.12, pp.1481-97, 2015.
DOI : 10.1586/14787210.2015.1093933

J. Hindler and R. Humphries, Colistin MIC Variability by Method for Contemporary Clinical Isolates of Multidrug-Resistant Gram-Negative Bacilli, Journal of Clinical Microbiology, vol.51, issue.6, pp.1678-84, 2013.
DOI : 10.1128/JCM.03385-12

J. Lo-ten-foe, A. De-smet, B. Diederen, J. Kluytmans, and P. Van-keulen, Comparative Evaluation of the VITEK 2, Disk Diffusion, Etest, Broth Microdilution, and Agar Dilution Susceptibility Testing Methods for Colistin in Clinical Isolates, Including Heteroresistant Enterobacter cloacae and Acinetobacter baumannii Strains, Antimicrobial Agents and Chemotherapy, vol.51, issue.10, pp.3726-3756, 2007.
DOI : 10.1128/AAC.01406-06

K. Dafopoulou, O. Zarkotou, E. Dimitroulia, C. Hadjichristodoulou, V. Gennimata et al., Comparative Evaluation of Colistin Susceptibility Testing Methods among Carbapenem-Nonsusceptible Klebsiella pneumoniae and Acinetobacter baumannii Clinical Isolates, Antimicrobial Agents and Chemotherapy, vol.59, issue.8, pp.4625-4655, 2015.
DOI : 10.1128/AAC.00868-15
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505270

A. Kwa, V. Tam, and M. Falagas, Polymyxins: a review of the current status including recent developments, Ann Acad Med Singap, vol.37, issue.10, pp.870-83, 2008.

Y. Park, J. Choi, D. Shin, and K. Ko, Correlation between overexpression and amino acid substitution of the PmrAB locus and colistin resistance in Acinetobacter baumannii, International Journal of Antimicrobial Agents, vol.37, issue.6, pp.525-555, 2011.
DOI : 10.1016/j.ijantimicag.2011.02.008

J. Gunn, The Salmonella PmrAB regulon: lipopolysaccharide modifications, antimicrobial peptide resistance and more, Trends in Microbiology, vol.16, issue.6, pp.284-90, 2008.
DOI : 10.1016/j.tim.2008.03.007

S. Kim, H. Choi, and K. Ko, Differential Expression of Two-Component Systems, pmrAB and phoPQ, with Different Growth phases of Klebsiella pneumoniae in the Presence or Absence of Colistin, Current Microbiology, vol.54, issue.1, pp.37-41, 2014.
DOI : 10.1007/s00284-014-0549-0

C. Raetz, Z. Guan, B. Ingram, D. Six, F. Song et al., Discovery of new biosynthetic pathways: the lipid A story, The Journal of Lipid Research, vol.50, issue.Supplement, pp.103-111, 2009.
DOI : 10.1194/jlr.R800060-JLR200

L. Fernandez, H. Jenssen, M. Bains, I. Wiegand, W. Gooderham et al., The Two-Component System CprRS Senses Cationic Peptides and Triggers Adaptive Resistance in Pseudomonas aeruginosa Independently of ParRS, Antimicrobial Agents and Chemotherapy, vol.56, issue.12, pp.6212-6234, 2012.
DOI : 10.1128/AAC.01530-12

J. Mcphee, M. Bains, G. Winsor, S. Lewenza, A. Kwasnicka et al., Contribution of the PhoP-PhoQ and PmrA-PmrB Two-Component Regulatory Systems to Mg2+-Induced Gene Regulation in Pseudomonas aeruginosa, Journal of Bacteriology, vol.188, issue.11, pp.3995-4006, 2006.
DOI : 10.1128/JB.00053-06

A. Beceiro, E. Llobet, J. Aranda, J. Bengoechea, M. Doumith et al., Phosphoethanolamine Modification of Lipid A in Colistin-Resistant Variants of Acinetobacter baumannii Mediated by the pmrAB Two-Component Regulatory System, Antimicrobial Agents and Chemotherapy, vol.55, issue.7, pp.3370-3379, 2011.
DOI : 10.1128/AAC.00079-11

E. Snitkin, A. Zelazny, J. Gupta, T. Palmore, P. Murray et al., Genomic insights into the fate of colistin resistance and Acinetobacter baumannii during patient treatment, Genome Research, vol.23, issue.7, pp.1155-62, 2013.
DOI : 10.1101/gr.154328.112

Y. Liu, Y. Wang, T. Walsh, L. Yi, R. Zhang et al., Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study, The Lancet Infectious Diseases, vol.16, issue.2, pp.161-169, 2016.
DOI : 10.1016/S1473-3099(15)00424-7

S. Schwarz and A. Johnson, Transferable resistance to colistin: a new but old threat: Table??1., Journal of Antimicrobial Chemotherapy, vol.71, issue.8, pp.2066-70, 2016.
DOI : 10.1093/jac/dkw274

J. Moffatt, M. Harper, P. Harrison, J. Hale, E. Vinogradov et al., Colistin Resistance in Acinetobacter baumannii Is Mediated by Complete Loss of Lipopolysaccharide Production, Antimicrobial Agents and Chemotherapy, vol.54, issue.12, pp.4971-4978, 2010.
DOI : 10.1128/AAC.00834-10

J. Li, C. Rayner, R. Nation, R. Owen, D. Spelman et al., Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumannii, Antimicrobial Agents and Chemotherapy, vol.50, issue.9, pp.2946-50, 2006.
DOI : 10.1128/AAC.00103-06
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1563544

J. Lee, Y. Park, E. Chung, I. Na, and K. Ko, Evolved resistance to colistin and its loss due to genetic reversion in Pseudomonas aeruginosa, Scientific Reports, vol.41, issue.1, p.25543, 2016.
DOI : 10.1128/AAC.01252-10

K. Lewis, Persister cells, dormancy and infectious disease, Nature Reviews Microbiology, vol.71, issue.1, pp.48-56, 2007.
DOI : 10.1128/AAC.00684-06

W. Couet, N. Gregoire, P. Gobin, P. Saulnier, D. Frasca et al., Pharmacokinetics of Colistin and Colistimethate Sodium After a Single 80-mg Intravenous Dose of CMS in Young Healthy Volunteers, Clinical Pharmacology & Therapeutics, vol.72, issue.6, pp.875-884, 2011.
DOI : 10.1128/AAC.01367-09

W. Couet, N. Gregoire, S. Marchand, and O. Mimoz, Colistin pharmacokinetics: the fog is lifting, Clinical Microbiology and Infection, vol.18, issue.1, pp.30-39, 2012.
DOI : 10.1111/j.1469-0691.2011.03667.x
URL : http://doi.org/10.1111/j.1469-0691.2011.03667.x

Z. Ma, J. Wang, R. Nation, J. Li, J. Turnidge et al., Renal Disposition of Colistin in the Isolated Perfused Rat Kidney, Antimicrobial Agents and Chemotherapy, vol.53, issue.7, pp.2857-64, 2009.
DOI : 10.1128/AAC.00030-09

X. Lu, T. Chan, C. Xu, L. Zhu, Q. Zhou et al., Human oligopeptide transporter 2 (PEPT2) mediates cellular uptake of polymyxins, Journal of Antimicrobial Chemotherapy, vol.71, issue.2, pp.403-415, 2016.
DOI : 10.1093/jac/dkv340

T. Suzuki, H. Yamaguchi, J. Ogura, M. Kobayashi, T. Yamada et al., Megalin Contributes to Kidney Accumulation and Nephrotoxicity of Colistin, Antimicrobial Agents and Chemotherapy, vol.57, issue.12, pp.6319-6343, 2013.
DOI : 10.1128/AAC.00254-13

L. Diao and B. Meibohm, Pharmacokinetics and Pharmacokinetic???Pharmacodynamic Correlations of Therapeutic Peptides, Clinical Pharmacokinetics, vol.96, issue.1, pp.855-68, 2013.
DOI : 10.1007/s40262-013-0079-0

M. Azad, J. Huang, M. Cooper, K. Roberts, P. Thompson et al., Structure???activity relationships for the binding of polymyxins with human ??-1-acid glycoprotein, Biochemical Pharmacology, vol.84, issue.3, pp.278-91, 2012.
DOI : 10.1016/j.bcp.2012.05.004

S. Cheah, J. Wang, V. Nguyen, J. Turnidge, J. Li et al., New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection, J Antimicrob Chemother, vol.70, issue.12, pp.3291-3298, 2015.

J. Li, R. Milne, R. Nation, J. Turnidge, T. Smeaton et al., Use of High-Performance Liquid Chromatography To Study the Pharmacokinetics of Colistin Sulfate in Rats following Intravenous Administration, Antimicrobial Agents and Chemotherapy, vol.47, issue.5, pp.1766-70, 2003.
DOI : 10.1128/AAC.47.5.1766-1770.2003

P. Matzneller, P. Gobin, E. Lackner, and M. Zeitlinger, Feasibility of microdialysis for determination of protein binding and target site pharmacokinetics of colistin in vivo, The Journal of Clinical Pharmacology, vol.57, issue.7, pp.431-438, 2015.
DOI : 10.1002/jcph.419

A. Al-khayyat and A. Aronson, Pharmacologic and Toxicologic Studies with the Polymyxins. III. Considerations Regarding Clinical Use in Dogs, Chemotherapy, vol.19, issue.2, pp.98-108, 1973.
DOI : 10.1159/000221444

A. Mohamed, I. Karaiskos, D. Plachouras, M. Karvanen, K. Pontikis et al., Application of a Loading Dose of Colistin Methanesulfonate in Critically Ill Patients: Population Pharmacokinetics, Protein Binding, and Prediction of Bacterial Kill, Antimicrobial Agents and Chemotherapy, vol.56, issue.8, pp.4241-4250, 2012.
DOI : 10.1128/AAC.06426-11

J. Kremer, J. Wilting, and L. Janssen, Drug binding to human alpha-1-acid glycoprotein in health and disease, Pharmacol Rev, vol.40, issue.1, pp.1-47, 1988.

A. Zavascki, L. Goldani, G. Cao, S. Superti, L. Lutz et al., Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients, Clinical Infectious Diseases, vol.47, issue.10, pp.1298-304, 2008.
DOI : 10.1086/592577

J. Huang, M. Blaskovich, R. Pelingon, S. Ramu, A. Kavanagh et al., Mucin Binding Reduces Colistin Antimicrobial Activity, Antimicrobial Agents and Chemotherapy, vol.59, issue.10, pp.5925-5956, 2015.
DOI : 10.1128/AAC.00808-15
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576126

R. Imberti, M. Cusato, P. Villani, L. Carnevale, G. Iotti et al., Steady-State Pharmacokinetics and BAL Concentration of Colistin in Critically Ill Patients After IV Colistin Methanesulfonate Administration, Chest, vol.138, issue.6, pp.1333-1342, 2010.
DOI : 10.1378/chest.10-0463

M. Boisson, M. Jacobs, N. Gregoire, P. Gobin, S. Marchand et al., Comparison of Intrapulmonary and Systemic Pharmacokinetics of Colistin Methanesulfonate (CMS) and Colistin after Aerosol Delivery and Intravenous Administration of CMS in Critically Ill Patients, Antimicrobial Agents and Chemotherapy, vol.58, issue.12, pp.7331-7340, 2014.
DOI : 10.1128/AAC.03510-14

S. Yapa, J. Li, K. Patel, J. Wilson, M. Dooley et al., Pulmonary and Systemic Pharmacokinetics of Inhaled and Intravenous Colistin Methanesulfonate in Cystic Fibrosis Patients: Targeting Advantage of Inhalational Administration, Antimicrobial Agents and Chemotherapy, vol.58, issue.5, pp.2570-2579, 2014.
DOI : 10.1128/AAC.01705-13

S. Nickel, C. Clerkin, M. Selo, and C. Ehrhardt, Transport mechanisms at the pulmonary mucosa: implications for drug delivery, Expert Opinion on Drug Delivery, vol.268, issue.3, pp.667-90, 2016.
DOI : 10.1111/cge.12392

T. Nakamura, T. Nakanishi, T. Haruta, Y. Shirasaka, J. Keogh et al., Transport of Ipratropium, an Anti-Chronic Obstructive Pulmonary Disease Drug, Is Mediated by Organic Cation/Carnitine Transporters in Human Bronchial Epithelial Cells: Implications for Carrier-Mediated Pulmonary Absorption, Molecular Pharmaceutics, vol.7, issue.1, pp.187-95, 2010.
DOI : 10.1021/mp900206j

D. Kofteridis, C. Alexopoulou, A. Valachis, S. Maraki, D. Dimopoulou et al., Aerosolized plus Intravenous Colistin versus Intravenous Colistin Alone for the Treatment of Ventilator???Associated Pneumonia: A Matched Case???Control Study, Clinical Infectious Diseases, vol.51, issue.11, pp.1238-1282, 2010.
DOI : 10.1086/657242

I. Korbila, A. Michalopoulos, P. Rafailidis, D. Nikita, G. Samonis et al., Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study, Clinical Microbiology and Infection, vol.16, issue.8, pp.1230-1236, 2010.
DOI : 10.1111/j.1469-0691.2009.03040.x

A. Michalopoulos, D. Fotakis, S. Virtzili, C. Vletsas, S. Raftopoulou et al., Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: A prospective study, Respiratory Medicine, vol.102, issue.3, pp.407-419, 2008.
DOI : 10.1016/j.rmed.2007.10.011

M. Tumbarello, D. Pascale, G. Trecarichi, E. , D. Martino et al., Effect of Aerosolized Colistin as Adjunctive Treatment on the Outcomes of Microbiologically Documented Ventilator-Associated Pneumonia Caused by Colistin-Only Susceptible Gram-Negative Bacteria, Chest, vol.144, issue.6, pp.1768-75, 2013.
DOI : 10.1378/chest.13-1018

A. Gontijo, N. Gregoire, I. Lamarche, P. Gobin, W. Couet et al., Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 2. Colistin, Antimicrobial Agents and Chemotherapy, vol.58, issue.7, pp.3950-3956, 2014.
DOI : 10.1128/AAC.02819-14

F. Ratjen, E. Rietschel, D. Kasel, R. Schwiertz, K. Starke et al., Pharmacokinetics of inhaled colistin in patients with cystic fibrosis, Journal of Antimicrobial Chemotherapy, vol.57, issue.2, pp.306-317, 2006.
DOI : 10.1093/jac/dki461

Z. Athanassa, S. Markantonis, M. Fousteri, P. Myrianthefs, E. Boutzouka et al., Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients, Intensive Care Medicine, vol.124, issue.4, pp.1779-86, 2012.
DOI : 10.1007/s00134-012-2628-7

S. Markantonis, N. Markou, M. Fousteri, N. Sakellaridis, S. Karatzas et al., Penetration of Colistin into Cerebrospinal Fluid, Antimicrobial Agents and Chemotherapy, vol.53, issue.11, pp.4907-4917, 2009.
DOI : 10.1128/AAC.00345-09
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2772309

M. Ziaka, S. Markantonis, M. Fousteri, P. Zygoulis, D. Panidis et al., Combined Intravenous and Intraventricular Administration of Colistin Methanesulfonate in Critically Ill Patients with Central Nervous System Infection, Antimicrobial Agents and Chemotherapy, vol.57, issue.4, pp.1938-1978, 2013.
DOI : 10.1128/AAC.01461-12

C. Antachopoulos, M. Karvanen, E. Iosifidis, B. Jansson, D. Plachouras et al., Serum and Cerebrospinal Fluid Levels of Colistin in Pediatric Patients, Antimicrobial Agents and Chemotherapy, vol.54, issue.9, pp.3985-3992, 2010.
DOI : 10.1128/AAC.01799-09

L. Jin, R. Nation, J. Li, and J. Nicolazzo, Species-Dependent Blood-Brain Barrier Disruption of Lipopolysaccharide: Amelioration by Colistin In Vitro and In Vivo, Antimicrobial Agents and Chemotherapy, vol.57, issue.9, pp.4336-4378, 2013.
DOI : 10.1128/AAC.00765-13

R. Imberti, M. Cusato, G. Accetta, V. Marino, F. Procaccio et al., Pharmacokinetics of Colistin in Cerebrospinal Fluid after Intraventricular Administration of Colistin Methanesulfonate, Antimicrobial Agents and Chemotherapy, vol.56, issue.8, pp.4416-4437, 2012.
DOI : 10.1128/AAC.00231-12

O. Mimoz, F. Petitpas, N. Gregoire, P. Gobin, S. Marchand et al., Colistin Distribution in the Peritoneal Fluid of a Patient with Severe Peritonitis, Antimicrobial Agents and Chemotherapy, vol.56, issue.7, pp.4035-4041, 2012.
DOI : 10.1128/AAC.00478-12

J. Guyonnet, B. Manco, L. Baduel, V. Kaltsatos, M. Aliabadi et al., Determination of a dosage regimen of colistin by pharmacokinetic/pharmacodynamic integration and modeling for treatment of G.I.T. disease in pigs, Research in Veterinary Science, vol.88, issue.2, pp.307-321, 2010.
DOI : 10.1016/j.rvsc.2009.09.001

G. Abis, S. Oosterling, H. Stockmann, G. Van-der-bij, M. Van-egmond et al., Perioperative selective decontamination of the digestive tract and standard antibiotic prophylaxis versus standard antibiotic prophylaxis alone in elective colorectal cancer patients, Dan Med J, vol.61, issue.4, p.4695, 2014.

B. Huttner, T. Haustein, I. Uckay, G. Renzi, A. Stewardson et al., Decolonization of intestinal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae with oral colistin and neomycin: a randomized, doubleblind , placebo-controlled trial, J Antimicrob Chemother, vol.68, issue.10, pp.2375-82, 2013.

W. Melsen, A. De-smet, J. Kluytmans, and M. Bonten, Selective decontamination of the oral and digestive tract in surgical versus non-surgical patients in intensive care in a cluster-randomized trial, British Journal of Surgery, vol.11, issue.2, pp.232-239, 2012.
DOI : 10.1002/bjs.7703

I. Oren, H. Sprecher, R. Finkelstein, S. Hadad, A. Neuberger et al., Eradication of carbapenem-resistant Enterobacteriaceae gastrointestinal colonization with nonabsorbable oral antibiotic treatment: A prospective controlled trial, American Journal of Infection Control, vol.41, issue.12, pp.1167-72, 2013.
DOI : 10.1016/j.ajic.2013.04.018

L. Saidel-odes, H. Polachek, N. Peled, K. Riesenberg, F. Schlaeffer et al., Conclusions., Infection Control & Hospital Epidemiology, vol.46, issue.01, pp.14-23, 2012.
DOI : 10.1097/QCO.0b013e32833ae214

A. Brink, J. Coetzee, C. Corcoran, C. Clay, D. Hari-makkan et al., Selection of Colistin Resistance as a Consequence of Selective Decontamination of the Gastrointestinal Tract, Journal of Clinical Microbiology, vol.51, issue.1, pp.369-72, 2013.
DOI : 10.1128/JCM.02234-12

T. Halaby, A. Naiemi, N. Kluytmans, J. Van-der-palen, J. Vandenbroucke-grauls et al., Emergence of Colistin Resistance in Enterobacteriaceae after the Introduction of Selective Digestive Tract Decontamination in an Intensive Care Unit, Antimicrobial Agents and Chemotherapy, vol.57, issue.7, pp.3224-3233, 2013.
DOI : 10.1128/AAC.02634-12

C. Lubbert, S. Faucheux, D. Becker-rux, S. Laudi, A. Durrbeck et al., Rapid emergence of secondary resistance to gentamicin and colistin following selective digestive decontamination in patients with KPC-2-producing Klebsiella pneumoniae: a single-centre experience, International Journal of Antimicrobial Agents, vol.42, issue.6, pp.565-70, 2013.
DOI : 10.1016/j.ijantimicag.2013.08.008

V. Strenger, T. Gschliesser, A. Grisold, G. Zarfel, G. Feierl et al., Orally administered colistin leads to colistin-resistant intestinal flora and fails to prevent faecal colonisation with extended-spectrum ??-lactamase-producing enterobacteria in hospitalised newborns, International Journal of Antimicrobial Agents, vol.37, issue.1, pp.67-76, 2011.
DOI : 10.1016/j.ijantimicag.2010.09.010
URL : https://hal.archives-ouvertes.fr/hal-00651645

S. Garonzik, J. Li, V. Thamlikitkul, D. Paterson, S. Shoham et al., Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients, Antimicrobial Agents and Chemotherapy, vol.55, issue.7, pp.3284-94, 2011.
DOI : 10.1128/AAC.01733-10

N. Grégoire, O. Mimoz, B. Mégarbane, E. Comets, D. Chatelier et al., New Colistin Population Pharmacokinetic Data in Critically Ill Patients Suggesting an Alternative Loading Dose Rationale, Antimicrobial Agents and Chemotherapy, vol.58, issue.12, pp.7324-7354, 2014.
DOI : 10.1128/AAC.03508-14

D. Plachouras, M. Karvanen, L. Friberg, E. Papadomichelakis, A. Antoniadou et al., Population Pharmacokinetic Analysis of Colistin Methanesulfonate and Colistin after Intravenous Administration in Critically Ill Patients with Infections Caused by Gram-Negative Bacteria, Antimicrobial Agents and Chemotherapy, vol.53, issue.8, pp.3430-3436, 2009.
DOI : 10.1128/AAC.01361-08

R. Nation, S. Garonzik, V. Thamlikitkul, E. Giamarellos-bourboulis, A. Forrest et al., Dosing guidance for intravenous colistin in critically-ill patients, Clinical Infectious Diseases
DOI : 10.1093/cid/ciw839

I. Karaiskos, L. Friberg, K. Pontikis, K. Ioannidis, V. Tsagkari et al., Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients, Antimicrobial Agents and Chemotherapy, vol.59, issue.12, pp.7240-7248, 2015.
DOI : 10.1128/AAC.00554-15

K. Vardakas, K. Rellos, N. Triarides, and M. Falagas, Colistin loading dose: evaluation of the published pharmacokinetic and clinical data, International Journal of Antimicrobial Agents, vol.48, issue.5, pp.475-84, 2016.
DOI : 10.1016/j.ijantimicag.2016.08.009

A. European-medicines, Committee for Medicinal Products for Human Use (CHMP) Assessment report. Polymyxinbased products, 2014.

R. Nation, S. Garonzik, J. Li, V. Thamlikitkul, E. Giamarellos-bourboulis et al., Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?, Clinical Infectious Diseases, vol.62, issue.5, pp.552-560, 2016.
DOI : 10.1093/cid/civ964
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741361

M. Jacobs, N. Gregoire, B. Megarbane, P. Gobin, D. Balayn et al., Population Pharmacokinetics of Colistin Methanesulfonate and Colistin in Critically Ill Patients with Acute Renal Failure Requiring Intermittent Hemodialysis, Antimicrobial Agents and Chemotherapy, vol.60, issue.3, pp.1788-93, 2016.
DOI : 10.1128/AAC.01868-15

P. Honore, R. Jacobs, S. Lochy, D. Waele, E. Van-gorp et al., Acute respiratory muscle weakness and apnea in a critically ill patient induced by colistin neurotoxicity: key potential role of hemoadsorption elimination during continuous venovenous hemofiltration, International Journal of Nephrology and Renovascular Disease, vol.6, pp.107-118, 2013.
DOI : 10.2147/IJNRD.S42791

A. Jitmuang, R. Nation, P. Koomanachai, G. Chen, H. Lee et al., Extracorporeal clearance of colistin methanesulphonate and formed colistin in end-stage renal disease patients receiving intermittent haemodialysis: implications for dosing, Journal of Antimicrobial Chemotherapy, vol.70, issue.6, pp.1804-1815, 2015.
DOI : 10.1093/jac/dkv031

S. Luque, L. Sorli, J. Li, S. Collado, F. Barbosa et al., Effective removal of colistin methanesulphonate and formed colistin during intermittent haemodialysis in a patient infected by polymyxin-only-susceptible Pseudomonas aeruginosa

S. Marchand, J. Frat, F. Petitpas, F. Lemaitre, P. Gobin et al., Removal of colistin during intermittent haemodialysis in two critically ill patients, Journal of Antimicrobial Chemotherapy, vol.65, issue.8, pp.1836-1843, 2010.
DOI : 10.1093/jac/dkq185

N. Markou, M. Fousteri, S. Markantonis, B. Zidianakis, D. Hroni et al., Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: an observational study, Journal of Antimicrobial Chemotherapy, vol.67, issue.10, pp.2459-62, 2012.
DOI : 10.1093/jac/dks257

M. Karvanen, D. Plachouras, L. Friberg, E. Paramythiotou, E. Papadomichelakis et al., Colistin Methanesulfonate and Colistin Pharmacokinetics in Critically Ill Patients Receiving Continuous Venovenous Hemodiafiltration, Antimicrobial Agents and Chemotherapy, vol.57, issue.1, pp.668-71, 2013.
DOI : 10.1128/AAC.00985-12
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3535942

I. Karaiskos, L. Friberg, L. Galani, K. Ioannidis, E. Katsouda et al., Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration, International Journal of Antimicrobial Agents, vol.48, issue.3, pp.337-378, 2016.
DOI : 10.1016/j.ijantimicag.2016.06.008

E. Fiaccadori, E. Antonucci, S. Morabito, A. Avolio, U. Maggiore et al., Colistin Use in Patients With Reduced Kidney Function, American Journal of Kidney Diseases, vol.68, issue.2, pp.296-306, 2016.
DOI : 10.1053/j.ajkd.2016.03.421

J. Li, K. Coulthard, R. Milne, R. Nation, S. Conway et al., Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis, Journal of Antimicrobial Chemotherapy, vol.52, issue.6, pp.987-92, 2003.
DOI : 10.1093/jac/dkg468

S. Marchand, P. Diot, N. Gregoire, A. Henriet, P. Gobin et al., Plasma pharmacokinetics and sputum concentrations of colistin after nebulization or intravenous administration of colistin methansulphonate (CMS) to ambulatories cystic fibrosis patients, 52nd international conference on antimicrobial agents and chemotherapy (ICAAC), pp.9-12, 2012.

D. Banerjee and D. Stableforth, The Treatment of Respiratory Pseudomonas Infection in Cystic Fibrosis, Drugs, vol.43, issue.6, pp.1053-64, 2000.
DOI : 10.2165/00003495-200060050-00006

C. Hansen, T. Pressler, and N. Hoiby, Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15??years experience, Journal of Cystic Fibrosis, vol.7, issue.6, pp.523-553, 2008.
DOI : 10.1016/j.jcf.2008.06.009

A. Schuster, C. Haliburn, G. Doring, and M. Goldman, Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study, Thorax, vol.68, issue.4, pp.344-50, 2013.
DOI : 10.1136/thoraxjnl-2012-202059

J. Lee, S. Han, S. Jeon, T. Hong, W. Song et al., Population Pharmacokinetic Analysis of Colistin in Burn Patients, Antimicrobial Agents and Chemotherapy, vol.57, issue.5, pp.2141-2147, 2013.
DOI : 10.1128/AAC.00271-13

K. Mizuyachi, K. Hara, A. Wakamatsu, S. Nohda, and T. Hirama, Safety and pharmacokinetic evaluation of intravenous colistin methanesulfonate sodium in Japanese healthy male subjects, Current Medical Research and Opinion, vol.27, issue.12, pp.2261-70, 2011.
DOI : 10.1185/03007995.2011.626557

M. Falagas and S. Kasiakou, Toxicity of polymyxins: a systematic review of the evidence from old and recent studies, Critical Care, vol.10, issue.1, p.27, 2006.
DOI : 10.1186/cc3995

L. Dalfino, F. Puntillo, M. Ondok, A. Mosca, R. Monno et al., Colistin-associated Acute Kidney Injury in Severely Ill Patients: A Step Toward a Better Renal Care? A Prospective Cohort Study, Clinical Infectious Diseases, vol.61, issue.12, pp.611771-611778, 2015.
DOI : 10.1093/cid/civ717

K. Phe, M. Johnson, H. Palmer, and V. Tam, Validation of a Model To Predict the Risk of Nephrotoxicity in Patients Receiving Colistin, Antimicrobial Agents and Chemotherapy, vol.58, issue.11, pp.6946-6954, 2014.
DOI : 10.1128/AAC.03776-14

L. Sorli, S. Luque, S. Grau, N. Berenguer, C. Segura et al., Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study, BMC Infectious Diseases, vol.30, issue.5, p.380, 2013.
DOI : 10.1016/j.clinthera.2008.01.015

C. Deryke, A. Crawford, N. Uddin, and M. Wallace, Colistin Dosing and Nephrotoxicity in a Large Community Teaching Hospital, Antimicrobial Agents and Chemotherapy, vol.54, issue.10, pp.4503-4508, 2010.
DOI : 10.1128/AAC.01707-09

T. Kelesidis and M. Falagas, The safety of polymyxin antibiotics, Expert Opinion on Drug Safety, vol.54, issue.11, pp.1687-701, 2015.
DOI : 10.1111/j.1469-0691.2006.01559.x

R. Sirijatuphat, S. Limmahakhun, V. Sirivatanauksorn, R. Nation, J. Li et al., Preliminary Clinical Study of the Effect of Ascorbic Acid on Colistin-Associated Nephrotoxicity, Antimicrobial Agents and Chemotherapy, vol.59, issue.6, pp.3224-3256, 2015.
DOI : 10.1128/AAC.00280-15

B. Yun, M. Azad, C. Nowell, R. Nation, P. Thompson et al., Cellular Uptake and Localization of Polymyxins in Renal Tubular Cells Using Rationally Designed Fluorescent Probes, Antimicrobial Agents and Chemotherapy, vol.59, issue.12, pp.7489-96, 2015.
DOI : 10.1128/AAC.01216-15

H. Spapen, P. Honore, N. Gregoire, P. Gobin, J. De-regt et al., Convulsions and apnoea in a patient infected with New Delhi metallo-??-lactamase-1 Escherichia coli treated with colistin, Journal of Infection, vol.63, issue.6, pp.468-70, 2011.
DOI : 10.1016/j.jinf.2011.07.008

S. Antoniu and I. Cojocaru, Inhaled colistin for lower respiratory tract infections, Expert Opinion on Drug Delivery, vol.2010, issue.2, pp.333-375
DOI : 10.1183/09031936.02.00230602

M. Gurjar, Colistin for lung infection: an update, Journal of Intensive Care, vol.3, issue.1, p.3, 2015.
DOI : 10.1093/cid/cir934
URL : http://doi.org/10.1186/s40560-015-0072-9

O. Bargiacchi, D. Rosa, and F. , Intrathecal or intraventricular colistin: a review, Infez Med, vol.24, issue.1, pp.3-11, 2016.

C. Landersdorfer and R. Nation, Colistin: how should it be dosed for the critically ill? Semin Respir Crit Care Med, pp.126-161, 2015.
DOI : 10.1055/s-0034-1398390

J. Horcajada, L. Sorli, S. Luque, N. Benito, C. Segura et al., Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate, International Journal of Antimicrobial Agents, vol.48, issue.6, pp.725-732, 2016.
DOI : 10.1016/j.ijantimicag.2016.08.020

P. Bergen, J. Bulitta, A. Forrest, B. Tsuji, J. Li et al., Pharmacokinetic/Pharmacodynamic Investigation of Colistin against Pseudomonas aeruginosa Using an In Vitro Model, Antimicrobial Agents and Chemotherapy, vol.54, issue.9, pp.3783-3792, 2010.
DOI : 10.1128/AAC.00903-09

R. Dudhani, J. Turnidge, K. Coulthard, R. Milne, C. Rayner et al., Elucidation of the Pharmacokinetic/Pharmacodynamic Determinant of Colistin Activity against Pseudomonas aeruginosa in Murine Thigh and Lung Infection Models, Antimicrobial Agents and Chemotherapy, vol.54, issue.3, pp.1117-1141, 2010.
DOI : 10.1128/AAC.01114-09

A. Mohamed, O. Cars, and L. Friberg, A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing, Journal of Antimicrobial Chemotherapy, vol.69, issue.5, pp.1350-61, 2014.
DOI : 10.1093/jac/dkt520

I. Wiegand, K. Hilpert, and R. Hancock, Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances, Nature Protocols, vol.217, issue.2, pp.163-75, 2008.
DOI : 10.1038/nprot.2007.521

M. Karvanen, Optimisation of colistin dosage in the treatment of multiresistant gram-negative infections, 2013.

J. Li, J. Turnidge, R. Milne, R. Nation, and K. Coulthard, In Vitro Pharmacodynamic Properties of Colistin and Colistin Methanesulfonate against Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis, Antimicrobial Agents and Chemotherapy, vol.45, issue.3, pp.781-786, 2001.
DOI : 10.1128/AAC.45.3.781-785.2001

A. Poudyal, B. Howden, J. Bell, W. Gao, R. Owen et al., In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae, Journal of Antimicrobial Chemotherapy, vol.62, issue.6, pp.1311-1319, 2008.
DOI : 10.1093/jac/dkn425

C. Tan, J. Li, and R. Nation, Activity of Colistin against Heteroresistant Acinetobacter baumannii and Emergence of Resistance in an In Vitro Pharmacokinetic/Pharmacodynamic Model, Antimicrobial Agents and Chemotherapy, vol.51, issue.9, pp.3413-3418, 2007.
DOI : 10.1128/AAC.01571-06

P. Bergen, J. Li, R. Nation, J. Turnidge, K. Coulthard et al., Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model, Journal of Antimicrobial Chemotherapy, vol.61, issue.3, pp.636-678, 2008.
DOI : 10.1093/jac/dkm511

J. Bulitta, J. Yang, L. Yohonn, N. Ly, S. Brown et al., Attenuation of Colistin Bactericidal Activity by High Inoculum of Pseudomonas aeruginosa Characterized by a New Mechanism-Based Population Pharmacodynamic Model, Antimicrobial Agents and Chemotherapy, vol.54, issue.5, pp.2051-62, 2010.
DOI : 10.1128/AAC.00881-09

S. Cheah, J. Li, B. Tsuji, A. Forrest, J. Bulitta et al., Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance, Antimicrobial Agents and Chemotherapy, vol.60, issue.7, pp.3921-3954, 2016.
DOI : 10.1128/AAC.02927-15

A. Mohamed, O. Cars, and L. Friberg, A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Clinical PK and PD of Colistin Author's personal copy Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing

O. Cirioni, R. Ghiselli, C. Silvestri, W. Kamysz, F. Orlando et al., Efficacy of Tachyplesin III, Colistin, and Imipenem against a Multiresistant Pseudomonas aeruginosa Strain, Antimicrobial Agents and Chemotherapy, vol.51, issue.6, pp.2005-2015, 2007.
DOI : 10.1128/AAC.01576-06

X. Di, R. Wang, B. Liu, X. Zhang, W. Ni et al., In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomas aeruginosa, The Journal of Antibiotics, vol.58, issue.9, pp.551-556, 2015.
DOI : 10.1038/ja.2015.27

P. Gaibani, D. Lombardo, R. Lewis, M. Mercuri, S. Bonora et al., In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates, Journal of Antimicrobial Chemotherapy, vol.69, issue.7, pp.1856-65, 2014.
DOI : 10.1093/jac/dku065

N. Gordon, K. Png, and D. Wareham, Potent Synergy and Sustained Bactericidal Activity of a Vancomycin-Colistin Combination versus Multidrug-Resistant Strains of Acinetobacter baumannii, Antimicrobial Agents and Chemotherapy, vol.54, issue.12, pp.5316-5338, 2010.
DOI : 10.1128/AAC.00922-10

M. Hornsey and D. Wareham, In Vivo Efficacy of Glycopeptide-Colistin Combination Therapies in a Galleria mellonella Model of Acinetobacter baumannii Infection, Antimicrobial Agents and Chemotherapy, vol.55, issue.7, pp.3534-3541, 2011.
DOI : 10.1128/AAC.00230-11

L. Minh, V. , T. K. Nhu, N. , V. Phat et al., In vitro activity of colistin in antimicrobial combination against carbapenem-resistant Acinetobacter baumannii isolated from patients with ventilator-associated pneumonia in Vietnam, Journal of Medical Microbiology, vol.64, issue.10, pp.1162-1171, 2015.
DOI : 10.1099/jmm.0.000137

B. Liu, Y. Liu, X. Di, X. Zhang, R. Wang et al., Colistin and anti-Gram-positive bacterial agents against Acinetobacter baumannii, Revista da Sociedade Brasileira de Medicina Tropical, vol.47, issue.4, pp.451-457, 2014.
DOI : 10.1590/0037-8682-0081-2014
URL : http://doi.org/10.1590/0037-8682-0081-2014

N. Ly, J. Bulitta, G. Rao, C. Landersdorfer, P. Holden et al., : profiling the time course of synergistic killing and prevention of resistance, Journal of Antimicrobial Chemotherapy, vol.70, issue.5, pp.1434-1476, 2015.
DOI : 10.1093/jac/dku567

M. Marie, L. Krishnappa, A. Alzahrani, M. Mubaraki, and A. Alyousef, A prospective evaluation of synergistic effect of sulbactam and tazobactam combination with meropenem or colistin against multidrug resistant Acinetobacter baumannii

C. Mitsugui, M. Tognim, C. Cardoso, F. Carrara-marroni, and L. Garcia, In vitro activity of polymyxins in combination with ??-lactams against clinical strains of Pseudomonas aeruginosa, International Journal of Antimicrobial Agents, vol.38, issue.5
DOI : 10.1016/j.ijantimicag.2011.06.012

W. Ni, J. Cui, B. Liang, Y. Cai, N. Bai et al., In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant Acinetobacter baumannii, The Journal of Antibiotics, vol.22, issue.12, pp.705-713, 2013.
DOI : 10.1128/AAC.32.1.42

W. Sheng, J. Wang, S. Li, Y. Lin, A. Cheng et al., Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU, Diagnostic Microbiology and Infectious Disease, vol.70, issue.3, pp.380-386, 2011.
DOI : 10.1016/j.diagmicrobio.2011.03.003

T. Tangden, R. Hickman, P. Forsberg, P. Lagerback, C. Giske et al., Evaluation of Double- and Triple-Antibiotic Combinations for VIM- and NDM-Producing Klebsiella pneumoniae by In Vitro Time-Kill Experiments, Antimicrobial Agents and Chemotherapy, vol.58, issue.3, pp.1757-62, 2014.
DOI : 10.1128/AAC.00741-13

D. Wareham, N. Gordon, and M. Hornsey, In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii, Journal of Antimicrobial Chemotherapy, vol.66, issue.5, pp.1047-51, 2011.
DOI : 10.1093/jac/dkr069

H. Yang, N. Lv, L. Hu, Y. Liu, J. Cheng et al., model, Infectious Diseases, vol.48, issue.3, pp.189-94, 2016.
DOI : 10.1128/AAC.02501-12
URL : https://hal.archives-ouvertes.fr/hal-01091232

G. Leite, M. Oliveira, L. Perdigão-neto, C. Rocha, T. Guimarães et al., Antimicrobial Combinations against Pan-Resistant Acinetobacter baumannii Isolates with Different Resistance Mechanisms, PLOS ONE, vol.59, issue.3, p.151270, 2016.
DOI : 10.1371/journal.pone.0151270.s001
URL : http://doi.org/10.1371/journal.pone.0151270

L. Oleksiuk, M. Nguyen, E. Press, C. Updike, O. Hara et al., In Vitro Responses of Acinetobacter baumannii to Two- and Three-Drug Combinations following Exposure to Colistin and Doripenem, Antimicrobial Agents and Chemotherapy, vol.58, issue.2, pp.1195-1204, 2014.
DOI : 10.1128/AAC.01779-13

C. Vidaillac, L. Benichou, and R. Duval, In Vitro Synergy of Colistin Combinations against Colistin-Resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae Isolates, Antimicrobial Agents and Chemotherapy, vol.56, issue.9, pp.4856-61, 2012.
DOI : 10.1128/AAC.05996-11

A. Mohamed, A. Kristoffersson, M. Karvanen, E. Nielsen, O. Cars et al., as quantified in a PK/PD model, Journal of Antimicrobial Chemotherapy, vol.71, issue.5, pp.1279-90, 2016.
DOI : 10.1093/jac/dkv488

R. Dudhani, J. Turnidge, R. Nation, and J. Li, fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models, Journal of Antimicrobial Chemotherapy, vol.65, issue.9, pp.1984-90, 2010.
DOI : 10.1093/jac/dkq226

B. Fan, J. Guan, X. Wang, and Y. Cong, Activity of Colistin in Combination with Meropenem, Tigecycline, Fosfomycin, Fusidic Acid, Rifampin or Sulbactam against Extensively Drug-Resistant Acinetobacter baumannii in a Murine Thigh-Infection Model, PLOS ONE, vol.40, issue.6, p.157757, 2016.
DOI : 10.1371/journal.pone.0157757.s001

G. Michail, M. Labrou, V. Pitiriga, S. Manousaka, N. Sakellaridis et al., Activity of Tigecycline in Combination with Colistin, Meropenem, Rifampin, or Gentamicin against KPC-Producing Enterobacteriaceae in a Murine Thigh Infection Model, Antimicrobial Agents and Chemotherapy, vol.57, issue.12, pp.6028-6061, 2013.
DOI : 10.1128/AAC.00891-13

H. Demiraslan, G. Dinc, S. Ahmed, F. Elmali, G. Metan et al., sepsis in corticosteroid receipt mice: tigecycline or colistin monotherapy versus tigecycline/colistin combination, Journal of Chemotherapy, vol.16, issue.5, pp.276-81, 2014.
DOI : 10.1111/1469-0691.12091

J. Lenhard, R. Nation, and B. Tsuji, Synergistic combinations of polymyxins, International Journal of Antimicrobial Agents, vol.48, issue.6, pp.607-620, 2016.
DOI : 10.1016/j.ijantimicag.2016.09.014
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237374

X. Dong, F. Chen, Y. Zhang, H. Liu, Y. Liu et al., In vitro activities of rifampin, colistin, sulbactam and tigecycline tested alone and in combination against extensively drug-resistant Acinetobacter baumannii, The Journal of Antibiotics, vol.38, issue.9, pp.677-80, 2014.
DOI : 10.3349/ymj.2012.53.5.974